Shopping Cart 0
Cart Subtotal
USD 0

CytoSorbents Corp (CTSO)-Product Pipeline Analysis, 2017 Update

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 1500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 2250
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that specializes in the development of blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriously ill patients by reducing excessive cytokines and bacterial toxins. CytoSorb is also being administered during and after cardiac surgery to prevent post-operative complications such as multiple organ failure. The company offers VetResQ, a blood purification adsorber, to help treat excessive inflammation and toxic injury in animals. The company offers its products through a network of distributors across Europe, the Middle East and Asia Pacific. CytoSorbents is headquartered in Monmouth Junction, New Jersey, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

The report analyzes all pipeline products in development for the company CytoSorbents Corp

The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

The report provides detailed description of products in development, technical specification and functions

The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

To formulate effective Research & Development strategies

Develop market-entry and market expansion strategies

Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

CytoSorbents Corp Company Overview 5

CytoSorbents Corp Company Snapshot 5

CytoSorbents Corp Pipeline Products and Ongoing Clinical Trials Overview 6

CytoSorbents Corp-Pipeline Analysis Overview 9

CytoSorbents Corp-Key Facts 9

CytoSorbents Corp-Major Products and Services 10

CytoSorbents Corp Pipeline Products by Development Stage 11

CytoSorbents Corp Ongoing Clinical Trials by Trial Status 13

CytoSorbents Corp Pipeline Products Overview 15

BetaSorb 15

BetaSorb Product Overview 15

ContrastSorb 16

ContrastSorb Product Overview 16

CST 301 17

CST 301 Product Overview 17

CytoSorb 18

CytoSorb Product Overview 18

CytoSorb Clinical Trial 19

CytoSorb-Cytokine Release Syndrome 24

CytoSorb-Cytokine Release Syndrome Product Overview 24

CytoSorb-XL 25

CytoSorb-XL Product Overview 25

DrugSorb 26

DrugSorb Product Overview 26

HemoDefend 27

HemoDefend Product Overview 27

CytoSorbents Corp-Key Competitors 28

CytoSorbents Corp-Key Employees 29

CytoSorbents Corp-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

CytoSorbents Corp, Recent Developments 31

Mar 28, 2017: Cytosorbents Strengthens Intellectual Property Portfolio With New Patents Issued In The U.S., China, Japan, Russia, And Australia 31

Mar 27, 2017: CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference 31

Mar 22, 2017: Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins Cytosorbents Scientific Advisory Board 31

Mar 20, 2017: CytoSorb Treatment of HLH-The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy 32

Mar 08, 2017: Cytosorbents Highlights Activities At The 22nd International Conference On Advances In Critical Care Nephrology 33

Mar 03, 2017: CytoSorbents Reports Record Quarterly and Full-Year 2016 Revenue 33

Feb 07, 2017: Cytosorbents To Present At The 19th Annual Bio CEO & Investor Conference 34

Jan 10, 2017: CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results 35

Dec 20, 2016: CytoSorbents Announces First Sales of New CytoSorb CPB Procedure Pack for Cardiac Surgery 35

Dec 12, 2016: Cytosorbents Receives $318,551 In Non-Dilutive Funding From The New Jersey Technology Business Tax Certificate Transfer Program 36

Appendix 37

Methodology 37

About GlobalData 39

Contact Us 39

Disclaimer 39


List Of Figure

List of Figures

CytoSorbents Corp Pipeline Products by Equipment Type 7

CytoSorbents Corp Pipeline Products by Development Stage 11

CytoSorbents Corp Ongoing Clinical Trials by Trial Status 13


List Of Table

List of Tables

CytoSorbents Corp Pipeline Products and Ongoing Clinical Trials Overview 6

CytoSorbents Corp Pipeline Products by Equipment Type 7

CytoSorbents Corp Pipeline Products by Indication 8

CytoSorbents Corp Ongoing Clinical Trials by Trial Status 8

CytoSorbents Corp, Key Facts 9

CytoSorbents Corp, Major Products and Services 10

CytoSorbents Corp Number of Pipeline Products by Development Stage 11

CytoSorbents Corp Pipeline Products Summary by Development Stage 12

CytoSorbents Corp Ongoing Clinical Trials by Trial Status 13

CytoSorbents Corp Ongoing Clinical Trials Summary 14

BetaSorb-Product Status 15

BetaSorb-Product Description 15

ContrastSorb-Product Status 16

ContrastSorb-Product Description 16

CST 301-Product Status 17

CST 301-Product Description 17

CytoSorb-Product Status 18

CytoSorb-Product Description 18

CytoSorb-Case-observation and Compassionate Use: Use of Extracorporeal Treatment with the Cytosorb-Adsorber for the Reduction of Postoperative Hyperinflammation and SIRS After Heart-surgery with the Use of a Heart-lung-machine 19

CytoSorb-Cytokine Adsorption in Sepsis and Acute Kidney Injury 19

CytoSorb-Cytokine Clearance with Cytoabsorbant Device During Cardiac Bypass: A Pilot Study 19

CytoSorb-Elimination of Antibiotics During Combined Continuous Renal Replacement Therapy and Cytosorb Adsorptive Therapy in Patients with Sepsis and Acute Kidney Injury 20

CytoSorb-Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy-A Randomized Study : EXCESS 20

CytoSorb-Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients with Rhabdomyolysis 20

CytoSorb-Immunomodulatory Effect of Extracorporeal Cytokine Adsorption in Cardiac Surgery 21

CytoSorb-International Registry on the Use of the CytoSorb-Adsorber in ICU Patients 21

CytoSorb-Myeloid-derived Supressor Cells in Uncomplicated Versus Complicated Patients after Cardiac Surgery 21

CytoSorb-Pancreatitis CytoSorbents (CytoSorb) Inflammatory Cytokine Removal: A Prospective Study 22

CytoSorb-Reduction of Inflammation Reaction to Extracorporeal Circulation in Cardiac Surgery by Interleukin Dialysis 22

CytoSorb-Removal of Cytokine on Cardiopulmonary Bypass with CytoSorb Compared to on- and Off-pump Myocardial Revascularization 22

CytoSorb-Removal of Cytokines During Cardiac Surgery 23

CytoSorb-The Effect of Early Cytokine Absorption on the Systemic Inflammatory Response Syndrome and Organ Dysfunction in the First 48 Hours of Septic Shock 23

CytoSorb-Cytokine Release Syndrome-Product Status 24

CytoSorb-Cytokine Release Syndrome-Product Description 24

CytoSorb-XL-Product Status 25

CytoSorb-XL-Product Description 25

DrugSorb-Product Status 26

DrugSorb-Product Description 26

HemoDefend-Product Status 27

HemoDefend-Product Description 27

CytoSorbents Corp, Key Employees 29

CytoSorbents Corp, Subsidiaries 30

Glossary 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Spectral Medical Inc, NxStage Medical Inc, Hologic Inc, HemoCleanse, Inc., Aethlon Medical Inc